Author: Editor

The standard of care for small-cell lung cancer (SCLC) had been unchanged for over 20 years, with platinum-based chemotherapy being the treatment of choice for extensive-stage (ES) disease. However, in 2018, the approval of Bristol-Myers Squibb’s Opdivo (nivolumab) in the second-line setting marked the beginning of the immunotherapy era for ES-SCLC. Sakis Paliouras, Oncology and Hematology Analyst at GlobalData, comments: “The US Food and Drug Administration (FDA) approved Genentech’s Tecentriq (atezolizumab) in combination with chemotherapy as a first-line treatment for ES-SCLC based on a 30% reduction in risk of death observed in the Phase III IMpower133 trial. This approval established…

Neal Shore, MD of Carolina Urologic Research Center @AtlanticUrology explains the randomized phase II study of sipuleucel-T with or without radium-223: how this affects clinicians and treatment today. ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio will be presented at the 2020 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers…

Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223 in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). Commonly asked questions: would this be a good way for patients with mildly symptomatic predominately with bone lesions to combine therapy? ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32,…

Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223 in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). ______________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio…

Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO and PBO in healthy volunteers:how developed is the MRI technology? ______________   New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving…

Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO and PBO in healthy volunteers:how developed is the MRI technology? ______________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology…

Neal Shore, MD of Carolina Urologic Research Center explains cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide compared to darolutamide and placebo in healthy volunteers. ____________ New data to be presented on the effect of Nubeqa® (darolutamide) on cerebral blood flow in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Presentations feature data on Xofigo® (radium Ra 223 dichloride), including real-world analyses and investigational combination therapies in men with certain types of prostate cancer Abstracts: 326, TPS384, 130, 32, 50, 56, 125, 89, 59, 136, 223, 236 WHIPPANY, N.J.–(BUSINESS WIRE)– Bayer announced today data from the Company’s evolving oncology portfolio…

– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients – – Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy Compared to Crizotinib –   Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of ALUNBRIG (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not…

NCCN celebrates 25th anniversary year; shares updates from oncology experts on leading-edge cancer management practices during NCCN 2020 Annual Conference in Orlando. #NCCN2020 — Cancer care providers will gather in Orlando on March 20-22 for the National Comprehensive Cancer Network® (NCCN®) 2020 Annual Conference: Celebrating 25 Years of NCCN. The three-day, in-person conference features more than 30 educational sessions on state-of-the-art practices in cancer care. Leading experts from NCCN’s 28 Member Institutions will present on new and emerging therapies, keys to optimization and implementation of treatment, and best practices in delivering oncology care across the continuum. “Cancer care has evolved dramatically since NCCN was founded 25…

Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first patient in Japan has initiated treatment in the global Phase 3 AGENT study.   Isofol’s drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC). The study is currently being conducted in the USA, Canada, Europe, Australia and now also in Japan. Isofol plans to start the trial in up to 15 clinics in Japan, in addition to the 80 clinics that are already open.   “A high pace is kept in our patient enrollment which enables the study’s…

While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation can have a contrary effect by promoting the survival of triple-negative breast cancer cells, according to research published online in the International Journal of Radiation Biology by Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute. Accounting for 15-20% of all breast cancers, triple-negative breast cancer is faster growing than other types of breast cancers. Dr. Sims-Mourtada’s latest study, “Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity…

Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder cancer. ____________ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEVTM (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.…

Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder cancer and commonly asked questions. ____________ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEVTM (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy…

Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder cancer. ____________ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEVTM (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.…

Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial – – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PADCEVTM (enfortumab vedotin-ejfv) in combination with Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. The FDA’s Breakthrough Therapy process is designed to…

Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: the importance of mutation testing.

Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: how this affects clinicians, patients and treatment today.

Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: does FGFR targeted therapy work better than an immune checkpoint inhibitor?

Arlene Siefker-Radtke, MD of @MDAndersonNews discusses the phase 1b/2 NORSE study on the treatment of metastatic urothelial carcinoma in patients with select FGFR alterations.

Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses fundamental mechanism for other clinical outcomes and phenotypes. ___________ In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment. Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and colleagues retrospectively analyzed data from 475…

Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses HSD3B1(1245C) – how this affects clinicians and treatment today. _________ In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment. Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and colleagues retrospectively analyzed data from…

Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic answers common questions between genetic variant and poor outcomes in men with metastatic prostate cancer; what is the frequency of this fast form of the enzyme? ______________ In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more…

Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses a link between genetic variant and poor outcomes in men with metastatic prostate cancer. _____________ In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer. This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment. Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and…

Caregiving responsibilities found to negatively affect academic productivity, primarily for men Hematologists who complete a mentored training program experience greater levels of academic success than those who do not; however, a study published today in Blood Advances suggests a slight discrepancy in success levels between male and female hematologists. The study, which examined the effect of caregiving responsibilities on academic success, identified that, on average, men had one more first- or senior-authored publication than women, and almost twice as many total publications. Surprisingly, the study found that self-identification as a caregiver was associated with decreased productivity for men but not women. The American Society…

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer explains how oral therapies will impact the treatment landscape in myeloid malignancies.

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer considers what we have learned from understanding real-world evidence (RWE) in older patients with acute myeloid malignancies.

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer elaborates on the role of venetoclax in treatment of myelodysplastic syndromes (MDS).

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, shares outcomes from the PRIMO study investigating duvelisib in peripheral T-cell lymphoma (PTCL).

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, tells us about some of the novel approaches in development for the treatment of peripheral T-cell lymphoma (PTCL).

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, discusses the most impressive studies in the treatment of peripheral T-cell lymphoma (PTCL) presented at ASH 2019.

Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, considers how peripheral T-cell lymphoma (PCL) therapy has evolved in recent years.

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the most impressive clinical presentations from ASH 2019 in the treatment of Hodgkin’s lymphoma.

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, tells us about the patient profile most suited for zanubrutinib in relapsed/refractory mantle cell lymphoma (MCL).

Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, shares the design and results of the Phase 2 study investigating first-line brentuximab vedotin plus nivolumab in older patients with Hodgkin’s lymphoma.

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his opinion on zanubrutinib as compared to other second-generation BTK inhibitors in the management of lymphoma.

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his impression of the pivotal clinical data that lead to the FDA approval of zanubrutinib.

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews speculates on therapies for front-line and relapsed mantle cell lymphoma.

Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews elaborates on the ZUMA-2 trial investigating anti-CD19 CAR-T cell therapy in mantle cell lymphoma.

Peter M. Voorhees, MD @LevineCancer shares the current thinking regarding treatment algorithms in relapsed/refractory multiple myeloma.

Peter M. Voorhees, MD @LevineCancer explains how daratumumab is changing the way multiple myeloma (MM) patients are treated today.

Peter M. Voorhees, MD @LevineCancer summarizes the design and outcomes of the Phase 2 Griffin study in newly diagnosed multiple myeloma (MM) patients.

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about the results of the Phase 3 ELEVATE TN study, investigating acalabrutinib combined with obinutuzumab or alone versus obinutuzumab plus chlorambucil in patients with treatment-naive chronic lymphocytic leukemia (CLL).

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL).

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers her impression of the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL).

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL).

Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about Veneto-STOP study presented at ASH 2019.

Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, regarding the ideal patient profile in relapsed or refractory mantle cell lymphoma (MCL) for treatment with zanubrutinib.

Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, offers his impression of the pivotal clinical data that lead to the recent FDA approval of zanubrutinib.

Max Topp, MD, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, on the development of a new risk management plan to potentially reduce the toxicity of CAR-T cell therapy.

Max Topp, MD, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, shares the long-term results of the ZUMA-1 trial presented at ASH 2019.

– ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer – – Prescription Drug User Fee Act (PDUFA) Target Action Date Set for June 23, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company’s supplemental New Drug Application (sNDA) to expand the use of ALUNBRIG (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ALUNBRIG is a next-generation tyrosine kinase inhibitor (TKI) that was designed to target…

 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced its plan to initiate a Phase 1/2 study evaluating a triple combination of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® (nivolumab) and BMS-986207, Bristol-Myers Squibb’s investigational anti-TIGIT antibody. The triple combination study is designed to evaluate the blockade of the three immune checkpoint pathways – PVRIG, TIGIT and PD-1, and will accelerate the clinical evaluation of Compugen’s science-driven DNAM axis hypothesis in various advanced solid tumors. The study is expected to commence in the second half of 2020, following…

Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impression of the pivotal clinical data that lead to the recent FDA approval of zanubrutinib.

Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impressions of the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the 1st line treatment of chronic lymphocytic leukemia (CLL).

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber shares thoughts on current treatment strategies for elderly acute myeloid leukemia (AML) patients.

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber elaborates on prognostic factors and the relationship to outcomes in acute myeloid leukemia (AML) patients.

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber offers his impression of the landscape for FLT3 inhibition in acute myeloid leukemia (AML).

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber provides opinion on whether all acute myeloid leukemia (AML) patients should be tested for FLT3 mutations.

Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber describes the landscape of mutations and targeted therapy in acute myeloid leukemia (AML).

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer discusses the prognostic factors in acute myeloid leukemia (AML) and how these factors relate to outcomes for patients.

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer offers her overall impression on the changing FLT3 inhibition landscape in acute myeloid leukemia (AML).

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether there are emerging mutations in FLT3 mutated relapsed/refractory acute myeloid leukemia (AML) that respond to gilteritinib.

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether all acute myeloid leukemia (AML) patients should be tested for FLT3.

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine @UCSFMedicine tells us about the outcomes of the Phase 3 ADMIRAL trial and why it is important to the management of acute myeloid leukemia.

Two-drug combination effective in lab studies against aggressive prostate tumors Research team identifies new approach to treating prostate cancer Metabolic targeting effective in lab study against aggressive prostate tumors Combining new, traditional approaches may prevent cancer recurrence A Roswell Park Comprehensive Cancer Center research team has identified a novel combination therapy that demonstrates a new approach to treating prostate cancer, reporting their findings in the journal Nature Communications. This new therapeutic strategy is the first to target metabolic processes uniquely important to prostate cancer — specifically, two enzymes in the connected polyamine catabolic pathway and the methionine salvage pathway.  Dr. Dominick Smiraglia and team…

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates on outcomes from the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the 1st line treatment of chronic lymphocytic lymphoma (CLL).

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, considers whether recent clinical data supports the use of CAR-T cell therapy in the management of lymphomas.

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers impressions of the Transcend-NHL data investigating the use of CAR-T cell therapy in chronic lymphocytic leukemia (CLL).

John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, considers whether minimal residual disease (MRD) is a valid endpoint when measuring treatment efficacy in chronic lymphocytic leukemia (CLL).

John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, tells us about the four-year update on the outcomes of the MURANO study, investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, on whether medical oncologists are adopting therapeutic biosimilars in treatment algorithms.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, offers opinion on the most promising studies in multiple myeloma (MM) presented at ASH 2019.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, regarding the role of proteasome inhibitors in maintenance therapy for multiple myeloma patients.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, explains the role of daratumumab as a maintenance therapy in the management of multiple myeloma (MM).

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer discusses the data investigating iberdomide presented at ASH 2019.

Adult cancer patients reported better physical and social function after undergoing CAR-T therapy Adult lymphoma patients whose disease was effectively treated with chimeric antigen receptor T-cell (CAR-T) therapy showed marked improvement on a variety of self-reported quality of life measures, according to a study published today in Blood Advances. The study offers evidence that CAR-T may not only extend cancer patients’ survival, but also improve their quality of life after treatment.Prior to the advent of CAR-T and other forms of cellular immunotherapy, patients with diffuse large B-cell lymphoma (DLBCL) had limited treatment options, and patients with advanced DLBCL had often already exhausted those…

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer provides opinion on the role of BCMA CAR-T cells in the management of multiple myeloma (MM).

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer considers the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients.

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer tells us about the design and outcomes of the Phase 3 CANDOR study in relapsed/refractory multiple myeloma.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope considers whether there is sufficient evidence to use bridging therapy before CAR-T therapy.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses clinical evidence supporting the use of CAR-T cell therapies in the treatment of aggressive B-cell lymphomas.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses clinical evidence supporting the use of CAR-T cell therapies in the treatment of aggressive B-cell lymphomas.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope shares her thoughts on the role of CAR-T cell therapy in the treatment of aggressive B-cell lymphomas.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the final data from its CTCL clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL), which was published and presented by Dr. M. Sokolowska-Wojdylo in conjunction with the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona, Spain on February 13, 2020.  The final results supported the safety of topical WP1220 and demonstrated a median improvement in the Composite Assessment of Index Lesion Severity (CAILS) score of 56% in treated (index) lesions for patients completing the…

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic factors in acute myeloid leukemia (AML) patients.

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some of the novel agents, targeted therapies, and emerging strategies in the management of acute myelogenous leukemia (AML).

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, elaborates on how the treatment of myelodysplastic syndromes is changing as a result of clinical data presented at ASH 2019.

Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering offers opinion on whether there is sufficient evidence to incorporate CAR-T cell therapies into acute leukemia treatment algorithms.

Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering shares clinical outcomes from the investigation of the vemurafenib combined with obinutuzumab in patients with hairy cell leukemia.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, tells us about the collaboration between the Leukemia and Lymphoma Society and the American Society of Hematology.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, elaborates on what the leukemia and lymphoma society is doing to help educate their membership on the novel agents and approaches.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, offers opinion on the most exciting progress being made in the treatment of lymphoma, leukemia and multiple myeloma.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, provides opinion on the most promising clinical presentations from ASH 2019.

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the results of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL).

In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer.   This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment.   Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and colleagues retrospectively analyzed data from 475 participants enrolled in a large, multi-center national clinical trial testing the efficacy of androgen deprivation…

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers whether off-the-shelf CAR-T cell therapy is becoming a reality.

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of off-the-shelf CAR natural killer (CAR NK) cell therapy in the treatment of B-cell malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai provides perspective on how oral therapies will impact the treatment landscape of myeloid malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai elaborates on the current approaches to treating elderly patients with myeloid malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai offers opinion on how the treatment of myelodysplastic syndromes (MDS) is changing, especially as a result of the clinical data presented at ASH 2019.

First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research, illustrating that use of the Company’s proprietary ADAPT Biotargeting Systemâ„¢ can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate…

Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, discusses if there is an association between minimal residual disease (MRD) and long-term survival outcomes in multiple myeloma (MM)

Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma patients.

Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to live for at least five years after being diagnosed. Going back in time to observe how cells with key gene mutations interact and become invasive would help researchers better understand how the cancer starts and identify it sooner. A pancreatic cancer “time machine” engineered by Purdue University researchers has revealed that the disease is even more unpredictable than previously thought: Cancer cells promote each other’s invasiveness when they grow together. The study, published in the journal Small, is just the beginning of…

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, shares his impression of the Phase 3 ASCERTAIN study investigating cedazuridine and decitabine versus decitabine in myelodysplastic syndromes (MDS).

Longeveron LLC, a leading developer of adult stem cell technologies for aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 2b Aging Frailty trial.  This double-blinded, randomized, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild to moderate frailty.     This 150 subject multicenter study is sponsored in part by a Small Business Innovation Research (SBIR) Grant from the National Institute of Aging (NIA), as part of the Geroscience initiative focused on preventing and treating age-related conditions, functional decline, and disability. “We are extremely pleased to achieve this…

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai discusses whether molecular analysis is appropriate and helpful in determining treatment approaches for myeloproliferative neoplasms.

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai tells us about his approach to the individualized management of myeloproliferative neoplasms.

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai shares outcomes from the MANIFEST study investigating CPI-0610 as a monotherapy or add-on to ruxolitinib in patients with myelofibrosis.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine compares the effectiveness of rasburicase versus allopurinol in cancer patients with hyperuricemia.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine describes those patient types more suited for treatment with rasburicase versus allopurinol.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine discusses the advantages of rasburicase compared to allopurinol in managing tumor lysis syndrome (TLS) in patients with renal dysfunction.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine considers whether there are particular patient types more prone to tumor lysis syndrome (TLS).

Immunomedics has developed an antibody drug conjugate (ADC) called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to triple negative breast cancer (TNBC) tumours, which highly express the glycoprotein Trop-2 and represents an unmet need within a highly treated cancer type. GlobalData’s pharmaceutical technology writer Allie Nawrat says: “The New Jersey-based firm has developed a novel ADC platform centred around its specialised hydrolysable linker, which delivers potent chemotherapy metabolites directly to cancer tumour sites and their microenvironments. “Immunomedics’ lead candidate, sacituzumab govitecan, is currently being developed for heavily treated TNBC patients. The company has received US Food and Drug Administration breakthrough…

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC explains how JNJ-4528 differs from other CAR-T products.

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed refractory multiple myeloma.

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC on how CAR-T cell therapy plays a role in the management of multiple myeloma.

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL).

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers whether minimal residual disease (MRD) is a valid endpoint when measuring the efficacy of treatment in chronic lymphocytic lymphoma (CLL).

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA tells us about the four-year update on the outcomes of the MURANO study investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic lymphoma.

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL).

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, tells us about the data with CAR-T cell therapy outside of clinical trials.

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, regarding the clinical evidence supporting CAR-T cell therapies in multiple myeloma.

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, provides his impression of the Transcend-NHL study investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL).

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, provides insight on the real-world evidence presented at ASH 2019 regarding CAR-T cell therapy in lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, discusses how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and other aggressive lymphomas.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the Phase 3 Dreamm-3 study, investigating belantamab versus pomalidomide and dexamethasone.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope describes the results of the Phase 1 study investigating CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in patients with relapsed/refractory multiple myeloma.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope elaborates on BCMA-directed strategies for multiple myeloma patients.

GRACE is very excited to bring to you more videos from our program, Supportive Care in Cancer Treatment.Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta speaks with Christi M. Walsh, MSN, CRNP, with Johns Hopkins University in Baltimore, MD. Christi Walsh and Dr. Gupta discuss Pancreatic Enzyme Replacement Therapy, or PERT.To donate to CancerGRACE, visit https://cancergrace.org/donate.For more, please visit http://cancerGRACE.org/.To join the conversation, visit https://cancergrace.org/forum.

Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta speaks with Shaalan Beg, MD, with UT Southwestern Medical Center in Dallas, TX . Dr. Beg and Dr. Gupta discuss Malignant Ascites, or fluid in the belly, in patients with cancer.To donate to CancerGRACE, visit https://cancergrace.org/donate.For more, please visit http://cancerGRACE.org/.To join the conversation, visit https://cancergrace.org/forum.

Source: https://www.spreaker.com/user/cancergrace/supportive-care-5-chemobrain-podcast We are very excited to bring to you this new program on supportive care in cancer treatment. In this video, our host Dr. Arjun Gupta speaks with his guest, Lysa Buonanno, who is a lung cancer patient and patient advocate. Lysa and Dr. Gupta discuss the often poorly understood subject of ‘chemobrain’, or attention, thinking or memory problems in patients with cancer. For more information on Chemobrain, please visit https://www.cancer.net/sites/cancer.net/files/asco_answers_chemobrain.pdf To join the conversation, visit https://cancergrace.org/forum. To find additional CancerGRACE resources, visit https://cancergrace.org. To donate to CancerGRACE, visit https://cancergrace.org/donate.

Source: https://www.spreaker.com/user/cancergrace/supportive-care-6-pert Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video, Dr. Gupta speaks with Christi M. Walsh, MSN, CRNP, with Johns Hopkins University in Baltimore, MD. Christi Walsh and Dr. Gupta discuss Pancreatic Enzyme Replacement Therapy, or PERT.

Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers his opinion on off-the-shelf CAR-T cell therapy.

Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes of the US CAR-T Cell Consortium study investigating bridging therapy prior to delivery of CAR-T cell therapy.

Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes of the US CAR-T Cell Consortium study investigating bridging therapy prior to delivery of CAR-T cell therapy.

Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews discusses how population-based outcomes in B-cell lymphomas are changing.

Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers perspective on the latest treatment trends for aggressive lymphomas.

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM shares the the primary and secondary endpoints of the ECHELON-2 study.

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM explains the purpose of targeting peripheral t-cell lymphoma (PTCL).

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM describes the ECHELON-2 data presented at ASH 2019.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, offers insight of the Phase 3 ICARIA-MM trial investigating isatuximab in relapsed/refractory multiple myeloma.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the STORM and Mammoth studies, investigating refractory multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies are used to manage relapsed/refractory multiple myeloma.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in the treatment of multiple myeloma.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC considers whether off-the-shelf CAR-T cell therapies are becoming a reality.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC offers impressions of the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL).

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC discusses the three-year survival analysis of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL) presented at ASH 2019.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC tells us about the results of the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy in mantle cell lymphoma (MCL) patients.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth explains how oncologists are using RWE today.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth provides examples of how real-world evidence (RWE) has impacted decision-making in oncology.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth defines real-world evidence (RWE) and explains how it can be used to aid physicians.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the future of off-the-shelf CAR-T cell therapy.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses off the-shelf CAR natural killer (CAR NK) cell therapy in treating B-cell malignancies.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, offers his insight on the recent data investigating the bi-specific CAR-T cell therapy.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the integration of stem cell transplantation into the treatment of myeloma.

Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews provides insight on current treatment strategies for elderly acute myeloid leukemia (AML) patients.

Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews describes the targeted therapy landscape in acute myeloid leukemia (AML) today.

Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews explains how the treatment of acute myeloid leukemia (AML) patients has evolved over the years.

Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews considers whether intensive chemotherapy should be used upfront to treat newly diagnosed acute myeloid leukemia (AML) patients.

Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses how combination therapies are evolving to unmet needs in follicular lymphoma.

Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone discusses the unmet needs of the Phase 1/2 study investigating obinutuzumab in relapsed/refractory follicular lymphoma.

Catherine Diefenbach, MD, Director, Clinical Lymphoma Program, Perlmutter Cancer Center @nyulangone tells us about the design and outcomes of the Phase 1/2 study investigating obinutuzumab in relapsed/refractory follicular lymphoma from ASH 2019.

Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma patients. Commonly asked questions are answered and he provides insight on standard treatment. _________ Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center of a new clinical trial at Providence Saint John’s Health Center’s Pacific Brain Tumor Center for patients diagnosed with chordoma, a rare, slow-growing cancer found in the bones at the base of the skull and the spine that is difficult to treat. Two chordoma patients who received the drug –…

Santosh Kesari, MD, PhD @DrKesari of @JohnWayneCI discusses a new clinical trial with the now approved drug, pemetrexed, for chordoma patients. __________ Brain Tumor Center affiliated with Providence Saint John’s Health Center The approved lung cancer drug pemetrexed is at the center of a new clinical trial at Providence Saint John’s Health Center’s Pacific Brain Tumor Center for patients diagnosed with chordoma, a rare, slow-growing cancer found in the bones at the base of the skull and the spine that is difficult to treat. Two chordoma patients who received the drug – approved by the FDA for lung cancer only – showed promising results…

Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI explains some common questions regarding PTEN patients. _________ Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different clinical presentations. In a new study published in JAMA Network Open, a team of researchers led by Charis Eng, MD, PhD, of Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute, discovered that copy number variations (CNVs) may act as genomic modifiers that influence the risk of autism spectrum disorder (ASD) and/or developmental delay (DD) versus cancer risk in individuals with PTEN mutations.   Germline mutations of the tumor suppressor gene PTEN are…

Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI clarifies genetic autism in PTEN patients. _______ Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different clinical presentations. In a new study published in JAMA Network Open, a team of researchers led by Charis Eng, MD, PhD, of Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute, discovered that copy number variations (CNVs) may act as genomic modifiers that influence the risk of autism spectrum disorder (ASD) and/or developmental delay (DD) versus cancer risk in individuals with PTEN mutations.   Germline mutations of the tumor suppressor gene PTEN are associated…

Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic speculates on the clinical impact of the TOURMALINE-AL1 study.

Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the side effects of the TOURMALINE-AL1 study presented at ASH 2019.

Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the outcomes of the TOURMALINE-AL1 study presented at ASH 2019.

Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the design of the TOURMALINE-AL1 study presented at ASH 2019.

Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA differentiates between various anti-CD-38 monoclonal antibodies and elaborates on the role of isatuximab in the management of multiple myeloma

Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the promising data on multiple myeloma data presented at ASH 2019.

Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of CAR-T cell therapy in multiple myeloma.

Andrew Cowan, MD Assistant Professor, Hematology/Oncology, University of Washington School of Medicine @SeattleCCA discusses the role of human BCMA CAR-T cells in the management of multiple myeloma.

Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, explains how academic and community oncologists can order a minimal residual disease (MRD) test.

Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, provides opinion on whether minimal residual disease (MRD) tests can be used to help guide treatment decisions.

Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham discusses how MRD can be used as a predictor of outcome.

Luciano J. Costa, MD, PhD @End_myeloma @uabmedicine Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham explains how measurement of minimal residual disease (MRD) is evolving as an endpoint in clinical trials.

John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses the design and objectives of the Phase Ib study assessing safety and preliminary efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers outlines the patient profile that is best suited for zanubrutinib in relapsed or refractory mantle cell lymphoma (MCL)

John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses how physicians should be thinking about the use of BTK inhibitors in the treatment of CLL.

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the role of BCMA CAR-T cells in the management of multiple myeloma.

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides information on the phase 3 ICARIA-MM study.

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains the difference in JNJ-4528 from other CAR-T cell products.

Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma

Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital discusses the long term survivors of AML bone marrow transplant implications.

Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital discusses immunotherapy changing the landscape of hematologic cancers.

Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital discusses the most promising clinical innovations in the treatment of hematologic cancers.

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the implications of real-world evidence for oncologists.

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the results and findings for idelalisib in patients with relapsed or refractory follicular lymphoma.

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence) has impacted the oncology community.

David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence) compliments clinical trial results.

Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope on seeking new solutions for providing proper access to innovative therapy.

Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope discusses the challenges cancer centers face when delivering innovative therapies.

Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope explains his philosophy regarding CAR-T cell therapy value to the care of patients.

Joseph Alvarnas, MD @cityofhope Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope discusses how to integrate clinical innovations into treatment algorithms in multidisciplinary teams.

Briggs Morrison, MD Chief Executive Officer of @Syndax discusses important details to note in this study. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31, 2020 issue and is currently available online. This study examined the activity of…

National Comprehensive Cancer Network to address HPV-related cancer prevention and treatment with World Cancer Day fundraiser and at upcoming NCCN 2020 Annual Conference. Learn more at NCCN.org/wcd and join the conversation online with hashtags #WorldCancerDay, #IAmAndIWill, and #NCCNGlobal.  — February 4, 2020, marks the 20th annual World Cancer Day. On this day, the National Comprehensive Cancer Network® (NCCN®)—a nonprofit alliance of leading cancer centers—is commemorating its 25th anniversary year by looking back at the tremendous progress made against cancer over the past quarter-century and looking forward to further define and advance high-quality, high-value, patient-centered cancer care globally. Earlier this year, the American Cancer Society (ACS) announced that the cancer death…

United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin® (dinutuximab) Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory small cell lung cancer (SCLC). The DISTINCT trial did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus using irinotecan alone. The safety profile of dinutuximab in DISTINCT was consistent with prior studies and the current Unituxin product label. Full data from the DISTINCT study will be made available through scientific disclosure at upcoming conferences and in peer-reviewed publications.   “We thank the principal investigators, patients and…

Briggs Morrison, MD Chief Executive Officer of @Syndax answers how likely is this to translate into being beneficial for patients and more common questions about NMP1 AML. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31,…

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that its open label, single arm US Phase 1 trial met its primary objective of demonstrating the safety of Liposomal Annamycin (“Annamycin”) in treating relapsed or refractory acute myeloid leukemia (“AML”). The Company also announced an update on interim enrollment, safety and efficacy data in its parallel Phase 1 trial in Europe, which continues with dose escalation, thus far without safety concerns. Safety of Annamycin in AML Patients The US Phase 1 trial met its…

Briggs Morrison, MD Chief Executive Officer of @Syndax discusses a preclinical study on the activity of menin-MLL inhibition for the treatment of NPM1 in AML. ___________ Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31, 2020 issue…

– If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with a fixed duration for patients with previously untreated chronic lymphocytic leukemia (CLL) – Represents third positive CHMP opinion for VENCLYXTO; further supports the growing utility of the therapy across multiple lines of CLL Positive opinion based on data from Phase 3 CLL14 trial, which showed that patients who completed one year of treatment with VENCLYXTO plus obinutuzumab had prolonged progression-free survival and higher rates of minimal residual disease negativity compared to patients receiving a standard of care chemoimmunotherapy regimen of…

Cleveland Clinic researchers have identified for the first time an explanation of why patients with identical PTEN mutations often have vastly different clinical presentations. In a new study published in JAMA Network Open, a team of researchers led by Charis Eng, MD, PhD, of Cleveland Clinic Lerner Research Institute’s Genomic Medicine Institute, discovered that copy number variations (CNVs) may act as genomic modifiers that influence the risk of autism spectrum disorder (ASD) and/or developmental delay (DD) versus cancer risk in individuals with PTEN mutations.   Germline mutations of the tumor suppressor gene PTEN are associated with a group of genetic disorders that increase the risk of certain cancers, cognitive and…

Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich answers commonly asked questions in pharmacogenomics and endocrine therapy in breast cancer.

– Application Supported by Results of Pivotal HER2CLIMB Trial -  – First Investigational Therapy in a Pivotal Trial to Include Patients with Metastatic HER2-Positive Breast Cancer with Active Brain Metastases -    EU Marketing Authorization Application (MAA) Follows Recent Submission of Tucatinib New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) – Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for tucatinib, in combination with trastuzumab and capecitabine, for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain…

Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich discusses endocrine therapy in breast cancer.

Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals’ lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML – Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). The article, “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” will be published in the journal’s January 31,…

Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time.   “We have developed stem cell models that are CRISPR-engineered to have tumor-associated driver mutations in glioblastoma, which harbor essentially all features of patient-derived tumors, including extrachromosomal DNA amplification,” said co-senior author Frank B. Funari, PhD, professor in the Department of Pathology at UC San Diego School of Medicine and head of the Laboratory of Tumor Biology in the…

Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer explains getting results down in oral paclitaxel: a Phase III clinical study in metastatic breast cancer.

Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer answers frequently asked questions on paclitaxel shown to be superior to IV paclitaxel: a Phase III clinical study in metastatic breast cancer.

Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer on paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a Phase III clinical study in metastatic breast cancer.

First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatin Second patient with stage 4 HER2+ metastatic breast cancer (MBC) shows 50 percent shrinkage in the primary tumor and no new signs of metastasis in the brain after treatment with leronlimab as a monotherapy CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional promising results from its…

– Improved clinical outcomes in advanced gastric/gastroesophageal junction cancer patients with DKK1-high tumors when treated with DKN-01 and anti PD-1 therapy – Tumoral DKK1 levels will be used to prospectively identify patients in subsequent studies in new collaboration with BeiGene Radiomic imaging analysis has identified a potentially useful biomarker to non-invasively evaluate DKK1 expression Leap Therapeutics, Inc. (Nasdaq: LPTX) today presented updated clinical data from its recently completed Phase 1/2 clinical trial of DKN-01 in patients with advanced or recurrent esophagogastric cancer (EGC) at the 2020 ASCO GI annual meeting. Updated response and survival data in the anti-PD-1/PD-L1 naïve gastric/gastroesophageal…

Philadelphia, PA (January 27, 2020) – Oncoceutics announced that the National Brain Tumor Society (NBTS) has committed to providing more than $200,000 in funding, with the potential for multiple years, to support a Phase II clinical trial of ONC201, the first imipridone dopamine receptor D2 antagonist (DRD2), in a molecular subset of high grade gliomas. The future clinical trial will evaluate the efficacy of single agent ONC201 in patients who have a recurrent form of high-grade glioma that exhibits low expression of epidermal growth factor receptor (EGFR), which is associated with elevated DRD2 expression and ONC201 sensitivity. The trial will…

Today, the American Society of Hematology (ASH) released new clinical practice guidelines on Sickle Cell Disease (SCD)-Related Transfusion Support. These guidelines are part of a series of five guidelines ASH is developing on SCD to provide updated treatment guidelines that reflect the newest evidence about the disease, ensuring the medical community can better treat SCD and people with SCD can make the best decisions for their care. The guidelines published in the Society’s peer-reviewed journal Blood Advances. Three more chapters are in development. ASH previously published SCD-Related Cardiopulmonary and Kidney Disease Guidelines in December 2019. “It is an incredibly exciting time with nearly limitless potential…

GRACE is very excited to bring to you our new program, Supportive Care in Cancer Treatment.Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta speaks with his guest, Lysa Buonanno, who is a lung cancer patient and patient advocate.Lysa and Dr. Gupta discuss the often poorly understood subject of ‘chemobrain’, or attention, thinking or memory problems in patients with cancer.To join the conversation, visit https://cancergrace.org/forum.To find additional CancerGRACE resources, visit https://cancergrace.org.To donate to CancerGRACE, visit https://cancergrace.org/donate.

  First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, Accurate and Actionable Genomic Information to Oncology Physicians and Patients Across Care Settings ArcherDX, Inc., today announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Personalized Cancer Monitoring (PCM) technology, a bespoke, minimally-invasive and highly-sensitive product intended for early-stage cancer treatment monitoring and recurrence surveillance. ArcherDX’s technology enables healthcare providers across community and academic care settings access to genomic information in their laboratory, saving critical time and allowing world-class, cost-effective care locally. The goal of the Breakthrough Devices…

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses what’s next in research for the TOUMRALINE-MM4 study. _________ Read here: https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses safety concerns regarding the trial. _________ Read here: https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/  

The American Society of Hematology (ASH) is pleased to announce that Gabriela Hobbs, MD, of Massachusetts General Hospital, and Oluwatoyosi Onwuemene, MD, MS, of Duke University have been selected to participate in the American Society of Hematology-Harold Amos Medical Faculty Development Program (ASH-AMFDP), a partnership between ASH and the Robert Wood Johnson Foundation (RWJF). The program, designed to increase the number of underrepresented minority scholars in the field of hematology with academic and research appointments, provides four-year research awards, totaling $420,000. Drs. Hobbs and Onwuemene will spend at least 70% of their research time under the mentorship of a senior…

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics explains how this is going to affect clinicians today and what clinicians should know about patients with the H3 K27 mutation. ________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic…

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses whether they will be submitting to the FDA or not.

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers what data has come out of the trial? _________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma patients. ONC201 achieved…

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine answers why ninlaro was compared to a placebo in TOURMALINE-MM4. Dr. Dimopoulous further discusses when the TOURMALINE-MM4 trial results will be presented.

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics answers how can we get access to this drug for glioblastoma? ___________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma…

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the design of the TOURMALINE-MM4 study and answers if the trail met its primary endpoint.

Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the phase 3 trial of ninlaro as first line maintenance therapy in multiple myeloma patients.

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses what’s next in ONC201 in adult recurrent glioblastoma. __________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma patients. ONC201 achieved…

Isabel Arrillaga-Romany, MD, PhD of @MGHNeuroOnc @Oncoceutics discusses the clinical efficacy of weekly ONC201 in adult recurrent glioblastoma. ________ Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma…

Data to include early analyses of Stivarga® (regorafenib) across HCC, CRC and GI cancers, including Phase 1b data in combination with immuno-oncology therapies New analysis of efficacy and safety from the NAVIGATE trial for Vitrakvi® (larotrectinib) in gastrointestinal tumors will be presented Abstracts: 564, 542, 135, 158, 824 Bayer will present new research from the Company’s oncology portfolio, including Stivarga® (regorafenib) and Vitrakvi® (larotrectinib), at the 2020 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium, taking place January 23-25 in San Francisco, California. The presentations will feature data on Stivarga in hepatocellular carcinoma (HCC) and gastric and colorectal cancers, as…

In Roswell Park study, 42% of patients who received gabapentin for pain managementrequired no narcotics Most patients treated for head and neck cancer experience painful mouth sores Team tested how well gabapentin controlled pain, at both low and high doses Both gabapentin and methadone can be more effective than standard approaches With nearly all patients who undergo treatment for cancers of the head and neck experiencing oral mucositis, or painful mouth sores, effective pain control is one of the main goals of physicians and care teams. Looking to provide more effective relief for patients while also reducing the need for…

Thomas Powles, MD, MBBS @tompowles1 of @QMBCI discusses how the JAVELIN study affects clinicians and treatment today.

Thomas Powles, MD, MBBS @tompowles1 of @QMBCI answers common questions regarding the JAVELIN study including what happens to patients with progression of disease?

Thomas Powles, MD, MBBS @tompowles1 of @QMBCI explains the phase III JAVELIN study in urothelial cancer.

Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy with external-beam radiotherapy in localized prostate cancer: what is next for treatment?

Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial.

Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: is there a correlation between the target volume of radiation?

World’s first combination of tumor-targeted, off-the-shelf PD-L1-targeted Natural Killer cells with IL-15 fusion protein (N-803) to induce immune system activation of both the NK and T-cells demonstrated complete response in second-line metastatic pancreatic cancer, confirmed by PET/CT scan. ·       Results consistent with durable complete responses recently reported in Triple Negative Breast Cancer (TNBC) when off-the-shelf CD-16 NK therapy was combined with ImmunityBio’s N-803. ·       Over 130 doses of PD-t-haNK cells safely administered in Phase 1 trial with no severe treatment-related adverse side effects. ·       NantKwest plans to initiate registration trials in recurrent metastatic TNBC and pancreatic cancer patients that failed standard of care. ·       N-803…

Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial.

Patrick Therasse, MD of Servier Group discusses Servier’s R&D efforts in oncology.